| abstract |
PCT No. PCT/GB93/00039 Sec. 371 Date Jul. 8, 1994 Sec. 102(e) Date Jul. 8, 1994 PCT Filed Jan. 11, 1993 PCT Pub. No. WO93/13805 PCT Pub. Date Jul. 22, 1993A compound comprises a target cell-specific portion, such as an antibody specific to tumour cell antigens, and an inactivating portion, such as an enzyme, capable of converting a substance which in its native state is able to inhibit the effect of a cytotoxic agent into a substance which has less effect against said cytotoxic agent. The prolonged action of a cytotoxic agent at tumour sites is therefore possible whilst protecting normal tissues from the effects of the cytotoxic agent. |